Business Context and Reporting Period
Company: Pluristem Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 5, 2012
Business Context: The registrant is a biopharmaceutical company focused on developing cell-based therapies. This filing reports a specific clinical milestone regarding its Placental eXpanded (PLX) cells.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical event and does not contain financial statements or performance metrics.
Material Changes
Clinical Milestone: On September 5, 2012, the company announced the successful administration of its PLX cells to a third patient at Hadassah Medical Center. This event marked the completion of a series of three life-saving compassionate use treatments.
Guidance, Outlook, and Risks
Management Commentary: The filing highlights the successful completion of the compassionate use treatment series as a significant operational event.
Guidance and Risks: The filing text does not provide specific financial guidance, future outlook projections, or a discussion of risks and contingencies beyond the context of the reported clinical event.
Key Facts for Investor Verification
- Verification of the clinical status and outcomes of the three compassionate use treatments involving PLX cells.
- Confirmation of the regulatory framework under which these compassionate use treatments were administered in Israel.
- Assessment of the potential impact of this clinical milestone on future regulatory filings or commercialization timelines.